Pharma firm Lupin today said its US-based subsidiary Lupin Pharmaceuticals Inc has received approval from the US drug regulator for Perindopril Erbumine tablets, used in treatment of heart disease.
The company has received final approval from the US Food and Drug Administration (US FDA) for its Perindopril Erbumine tablets in the strengths of 2mg, 4mg and 8mg, Lupin said in a statement to the Bombay Stock Exchange.
According to Mumbai-based drug manufacturer, "commercial shipments of the product will commence shortly."
The tablets are indicated for the treatment of patients with essential hypertension and can be used with conventional treatment for management of coronary artery disease, it said.
Headquartered in Baltimore, Lupin Pharmaceuticals Inc is the US wholly-owned subsidiary of Lupin Ltd.
Shares of Lupin were trading at Rs 1,397, down 0.76 per cent on BSE.